Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fangyiqing Fengshi Granules is a Traditional Chinese Medicine (TCM) formulation developed by Guizhou Liansheng Pharmaceutical Co., Ltd. specifically for the treatment of rheumatoid arthritis. The product is designed to dispel wind, eliminate dampness, and alleviate pain, addressing the TCM diagnosis of 'Bi-syndrome' characterized by joint swelling and restricted movement. The formulation typically includes extracts from medicinal plants such as *Stephania tetrandra* (Fangji), *Clematis chinensis* (Weilingxian), *Phellodendron amurense* (Huangbai), and *Atractylodes lancea* (Cangzhu). Its therapeutic effects are largely attributed to active alkaloids like tetrandrine, which exhibit potent anti-inflammatory and immunosuppressive properties by inhibiting pro-inflammatory cytokines and modulating immune signaling pathways. It is approved for marketing in China and is used as a pharmaceutical intervention for patients suffering from chronic inflammatory joint conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fangyiqing Fengshi Granules.